Browse Tag

Eisai

January 23, 2020

Eisai: Dayvigo (Lemborexant) Approved for Treatment of Insomnia in Japan

Eisai Co., Ltd. announced today that it has obtained the manufacturing and marketing approval in Japan for its in-house discovered orexin receptor antagonist DAYVIGO (2.5mg, 5mg, and 10mg tablets, lemborexant) for treatment of insomnia. DAYVIGO is a dual orexin receptor antagonist that inhibits orexin

March 17, 2021

DZNE and Eisai Enter Into Research Collaboration Agreement Aiming for Novel Drug Discovery for Neurodegenerative Disorders

Deutsches Zentrum fur Neurodegenerative Erkrankungen and Eisai Co., Ltd. today announced that

March 19, 2020

Eisai: All-case Surveillance Condition for Approval of “Actonel 17.5 mg tablets” for Treatment of Paget’s Disease of Bone Cleared in Japan

EA Pharma Co., Ltd. and its parent company Eisai Co., Ltd. announced

Go toTop